Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.81 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.81 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 12/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7782372 | 0.90 | AKR1C3 (0.71) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL10090683 | 0.89 | AKR1C3 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL11409315 | 0.85 | HPGD (0.69) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL10812989 | 0.85 | HPGD (0.69) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL10090711 | 0.83 | ALDH1A1 (0.68) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL10090704 | 0.83 | ALDH1A1 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL803089 | 0.80 | CA12 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL30361105 | 0.80 | CA12 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL29359256 | 0.80 | CA12 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 | |
| SCHEMBL710477 | 0.80 | CA12 (1.00) | AKR1C3AKR1C2AKR1C1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158390-A1 | Methods for Tumor Diagnosis and Therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-09 | — | — | US | disclosed |
| US-20160158390-A1 | Methods for Tumor Diagnosis and Therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-09 | — | — | US | disclosed |
| US-9186425-B2 | Methods for tumor diagnosis and therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186425-B2 | Methods for tumor diagnosis and therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140178298-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178298-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120213701-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-23 | — | — | US | disclosed |
| US-8168159-B2 | Compounds for tumor diagnosis and therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090285755-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-11-19 | — | — | US | disclosed |
| US-7514067-B2 | Complexing enzyme with antibody; trapping within tumor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213701-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | FOLH1, DNPEP, ENPEP | AKR1C3 1121/4885AKR1C2 854/4885AKR1C1 986/4885 |
| US-20090285755-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | FOLH1, DNPEP, ENPEP | AKR1C3 1121/4885AKR1C2 854/4885AKR1C1 986/4885 |
| US-20140178298-A1 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY | FOLH1, DNPEP, ENPEP | AKR1C3 1121/4885AKR1C2 854/4885AKR1C1 986/4885 |
| US-20160158390-A1 | Methods for Tumor Diagnosis and Therapy | FOLH1, DNPEP, ENPEP | AKR1C3 1121/4885AKR1C2 854/4885AKR1C1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.